United Therapeutics (UTHR) Income towards Parent Company (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Income towards Parent Company data on file, last reported at $274.9 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 14.68% year-over-year to $274.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 6.34% YoY), and the FY2025 full-year result was $1.3 billion, up 11.68% from the prior year.
• Income towards Parent Company slipped to $274.9 million in Q1 2026, from $364.3 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $364.3 million in Q4 2025 to a low of $116.0 million in Q2 2022.
• A 5-year average of $265.7 million and a median of $274.9 million in 2026 frame the typical range for Income towards Parent Company.
• Peak annual rise in Income towards Parent Company reached 747.7% in 2022, while the deepest fall reached 32.79% in 2022.
• Tracing UTHR's Income towards Parent Company over 5 years: stood at $132.1 million in 2022, then surged by 64.35% to $217.1 million in 2023, then surged by 38.78% to $301.3 million in 2024, then increased by 20.91% to $364.3 million in 2025, then retreated by 24.54% to $274.9 million in 2026.
• Business Quant data shows UTHR's Income towards Parent Company at $274.9 million in Q1 2026, $364.3 million in Q4 2025, and $338.7 million in Q3 2025.